Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 4;12:7255–7272. doi: 10.2147/IJN.S136726

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 Zhou et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Uptake of CLD/siRNA nanocomplexes by A375 cells and HeLa cells. (A and C) Flow cytometry analysis of fluorescence intensity cells treated with CLD/FAM-siRNA at 100 nM for 6 h. (B) A375 cells were incubated with cRGD peptide (15 μg/mL) or cRAD peptide (15 μg/mL) at 37°C for 30 min in the beginning, and then cellular uptake levels was measured by flow cytometry after cells treated with CLD/FAM-siRNA at 100 nM for 6 h. (D) Intracellular pathway investigation for four nanocomplexes in A375 cells. Channel ratio image of four nanocomplexes in cellular uptake (n=3).

Note: 3/3, 5/3, 5/5, 3/As, 5/As, siMB3 represent CLD/siRNA 20–25 (Table 2).

Abbreviations: CLD, cationic lipid material; siRNA, small interfering RNA; cRGD, cyclo(Arg-Gly-Asp-d-Phe-Lys[PEG-MAL]) peptide; cRAD, cyclo(Arg-Ala-Asp-D-Phe-Lys[PEG-MAL]) peptide.